Five things for pharma marketers to know: Friday, June 16, 2017
1. Apple is reportedly working to bring electronic health records to the iPhone, according to unnamed sources. The company is reportedly in discussions with developers, hospitals, and other industry groups about making the iPhone a repository for the entirety of an individual's health information. (CNBC)
2. The FDA plans to study the effect of placing disclosures “prominently and adjacently” to claims made in drug advertisements to see if consumers can effectively contextualize the information. The agency is accepting comments on the proposed study through August 14.
3. The Trump administration is reportedly preparing an executive order designed to address rising drug costs, according to unnamed sources. Officials are expected to raise the idea of value-based agreements, where drugmakers are compensated based on how well their product works. (Bloomberg)
4. New FDA commissioner Scott Gottlieb announced an initiative aimed at better regulating digital health tools. The agency's current thinking is to create a third-party certification for lower-risk digital health products and a streamlined process for higher-risk products. (FDA)
5. Amgen continues to face pushback on the cost of its PCSK9 inhibitor Repatha following a positive outcomes study. After the drug failed to show a statistically significant mortality benefit in its FOURIER outcomes trial, the Institute for Clinical and Economic Review plans to issue a lower value-based price benchmark for the drug. (BioPharmaDive)